Document is current
Any future updates will be listed below
-
Authors
Pallarès-Masmitjà, Maria https://orcid.org/0000-0002-7317-7793
Ivančić, Dimitrije
Mir-Pedrol, Júlia https://orcid.org/0000-0001-6104-9260
Jaraba-Wallace, Jessica
Tagliani, Tommaso
Oliva, Baldomero https://orcid.org/0000-0003-0702-0250
Rahmeh, Amal
Sánchez-Mejías, Avencia
Güell, Marc https://orcid.org/0000-0003-4000-7912
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (825825)
"la Caixa" Foundation (CI1800036, CF19-00010)
"la Caixa" Foundation
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (SAF2017-88784-R)
- License Information
-
More Information
Article History
Received: 30 October 2020
Accepted: 9 November 2021
First Online: 3 December 2021
Competing interests
: A.S.-M., D.I., M.G. and M.P.-M. have filed patent applications on FiCAT technology. Patent applicant: Pompeu Fabra University; application number: PCT/IB2020/055507; status of application: pending; specific aspect of manuscript covered in patent application: this patent application covered the general aspects of DNA binding proteins fused to integrases and transposases. Specifically, Fig. , Supplementary Fig. and preliminary data on activity characterization of some of the hyPB mutants included in Fig. were disclosed in this patent application. A.S.-M. and M.G. are shareholders of Integra Therapeutics, company that licensed FiCAT technology. The remaining authors declare no competing interests.
